12/8
08:07 am
ndra
ENDRA Life Sciences (NASDAQ:NDRA) had its price target lowered by analysts at Ascendiant Capital Markets from $38.00 to $30.00. They now have a "buy" rating on the stock.
High
Report
ENDRA Life Sciences (NASDAQ:NDRA) had its price target lowered by analysts at Ascendiant Capital Markets from $38.00 to $30.00. They now have a "buy" rating on the stock.
12/4
08:00 am
ndra
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
High
Report
ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use